

Worldwide Healthcare Trust PLC



Portfolio Manager



Samuel D. Isaly

Sven H. Borho

Information as at 30 November 2016

www.worldwidewh.com

[@WorldwideWH](https://twitter.com/WorldwideWH)

Investment Objective and Benchmark Index


To invest in the global healthcare sector with the objective of achieving a high level of capital growth. In order to achieve its investment objective, the Company invests worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It uses gearing, and derivative transactions to enhance returns and mitigate risk. Performance is measured against the MSCI World Health Care Index (net total return, sterling adjusted).

Cumulative Performance (%)

Trust: Worldwide Healthcare Trust PLC – NAV (ex income, total return; fully diluted)

Trust: Worldwide Healthcare Trust PLC – Share Price (total return)

Benchmark: MSCI World Health Care Index (net total return; £ adjusted)



Discrete Performance – Calendar Years (%)

Percentage Growth	2011	2012	2013	2014	2015	YTD
NAV	7.3	14.4	44.6	38.9	19.1	3.4
Share Price	6.5	20.3	47.1	39.6	13.9	8.6
Benchmark	10.7	12.2	33.6	25.6	12.7	8.2

Source: NAV (ex income total return; fully diluted) & Share Price (total return) – Morningstar. Index - Bloomberg. Past performance is not a guide to future performance.

Commentary

In November the NAV per share was down 1.7%, the share price was up 3.6%, and the MSCI World Health Care Index which was down 2.1%.

November was a month of two halves. Early in the month we saw the surprise U.S. Presidential election win by the Republican nominee, Donald Trump. Coupled with an unexpected “Republican sweep” of Congress, healthcare equities, in particular pharmaceutical and biotechnology stocks, rallied hard on the news. But shortly thereafter, investor apathy apparently set in, and as a result most of the healthcare gains waned into month end. Nevertheless, biotechnology stocks did close the month higher, thus leading to relative outperformance for the sector in November. Health Care Services, whilst a positive contributor on an absolute basis, was the largest alpha detractor in the month, as stock reactions there were very disparate after Mr. Trump’s victory.

In terms of individual stocks, Swiss-based Actelion was the largest contributor after the company was approached by Johnson & Johnson in an M&A bid. Incyte, an emerging biotech company, moved higher after the election and held its gains after a competitor’s data disappointed. Finally, Humana rallied after the election as investors viewed the managed care company as a “winner” under a Trump regime.

The largest detractor in November was Eli Lilly & Co. The company announced final Phase III results for their highly anticipated, potentially disease modifying therapy for the treatment of Alzheimer’s disease. Unfortunately, the trial failed to show a statistically significant difference compared to a placebo, disappointing both patients and investors. The stock was lower by more than 10% as a result. Further losses in the portfolio were mitigated by a partial stock replacement strategy using derivatives, thus losses there were limited to the premium paid to purchase call options ahead of the event. Other notable detractors in the month included Boston Scientific which saw profit taking in the aftermath of the election, and the hospital operator, HCA, which was lower as investors feared the potential for President Elect Trump to repeal the Affordable Care Act, a previous tailwind for the company.

Biographies

Samuel D. Isaly is the Managing Partner of OrbiMed. Mr. Isaly is one of the world’s foremost healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Mr. Isaly has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, and S.G. Warburg. Mr. Isaly launched OrbiMed’s asset management business in 1989. Mr. Isaly has a B.A. in Economics from Princeton University and a M.Sc. (Econ.) from The London School of Economics.

Sven H. Borho CFA, is a founding Partner of OrbiMed. Mr. Borho heads the public equity team and he is the portfolio manager for OrbiMed’s public equity and hedge funds. Mr. Borho has played an integral role in the growth of OrbiMed’s asset management activities. Mr. Borho started his career in 1991 when he joined OrbiMed’s predecessor firm as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Mr. Borho was promoted to portfolio manager. Mr. Borho studied business administration at Bayreuth University in Germany and received a M.Sc. (Econ.), Accounting and Finance, from The London School of Economics; he is a citizen of both Germany and Sweden.

Portfolio Manager Profile

OrbiMed Capital LLC (OrbiMed) is owned by six principals, including Samuel D. Isaly, and Sven Borho who have between them many years’ experience of investing in the pharmaceutical, biotechnology and healthcare sectors. The U.S. based company has over 90 investment professionals who carry out extensive research, involving company visits, developing an understanding of the commercial and scientific prospects for individual drugs. OrbiMed is registered as an investment adviser under the U.S. Securities and Exchange Commission (SEC). SEC registration does not imply a certain level of skill or training.

Investment Policy

The Company offers a superior UK-listed opportunity for capital appreciation through a diversified portfolio of worldwide pharmaceutical, biotechnology, healthcare equipment, healthcare technology and healthcare services companies. The Portfolio Manager seeks to reduce risk through extensive fundamental research, worldwide exposure, position limits, and balanced market capitalisations. The Company’s investment objective also allows gearing, through borrowing of up to 20% of net assets and a net exposure to derivative investments (excluding swaps) of up to 5% of the portfolio. Equity swaps may also be used, counterparty exposure here is limited to 12% of the portfolio at the time of acquisition.

Discount Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company’s shares through the use of share buybacks, with a view to limiting the discount to the ex income NAV per share at which the shares trade to no more than 6%. Shares bought back may be held in treasury for reissue at later dates at not more than the discount at which they were purchased, and in any event at a discount no greater than 5% to the prevailing cum income net asset value per share. Any shares left in treasury are cancelled around the time of the AGM.

Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers ("IFAs") to retail private investors. The shares are excluded from the Financial Conduct Authority's ("FCA's") restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.

Worldwide Healthcare Trust PLC

10 Largest Holdings as at 30 November 2016*

Name	Region	Total
Merck & Co	North America	4.3
Intuitive Surgical	North America	4.3
Boston Scientific	North America	4.1
HCA Holdings	North America	3.6
Alexion Pharmaceuticals	North America	3.5
Wright Medical	Europe	3.4
Incyte	North America	3.1
Amgen	North America	3.1
Humana	North America	2.8
Biogen	North America	2.6
Total		34.8

All data in the above includes any derivative, convertible or fixed bond exposures as an economically equivalent position in the underlying asset.

Sector, Geographical* & Asset Class Breakdown at 30 November 2016**

Large Caps	70.0%	North America	62.6%	Equities	85.9%
Small Caps	30.0%	Europe	16.0%	Equity Swaps	10.5%
Total	100.0%	Emerging Markets	15.1%	Variable Bonds	2.0%
		Asia	6.3%	Options	0.9%
		Total	100.0%	Convertible Bonds	0.7%
				Total	100.0%

Source: All portfolio information sourced from Frostrow Capital LLP.

*Geographical analysis based on country of incorporation.

**Calculation based on economic exposure and expressed as a % of the total economic exposure. This includes all derivatives as an economically equivalent position in the underlying asset.

Share Price Total Return on £100 as at 30 November 2016 (£)

1 year	114.4
3 years	170.3
5 years	323.9

Source: Morningstar. Past performance is not a guide to future performance.

Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	Nov 11- Nov 12	Nov 12- Nov 13	Nov 13- Nov 14	Nov 14- Nov 15	Nov 15- Nov 16
NAV	18.3	42.7	41.2	13.1	8.2
Share Price	24.1	53.3	39.2	7.0	14.4
Benchmark	18.5	32.7	28.2	6.3	12.1

Source: NAV (ex income total return; fully diluted) & Share Price (total return) – Morningstar. Index - Bloomberg. Past performance is not a guide to future performance.

Awards

Winner: Investment Week, Investment Company of the Year 2016, Specialist (including Hedge Funds) Category

Winner: What Investment Trust Awards 2014 Best Sector Specialist Investment Trust

Highly Commended: Money Observer Trust Awards 2014, 2015 Best Large Trust

Rated Fund: Money Observer Rated Funds 2015

Important Information

Worldwide Healthcare Trust PLC (the "Company") is a UK investment trust premium listed on the London Stock Exchange and is a member of the Association of Investment Companies. As this Company may implement a gearing policy investors should be aware that the share price movement may be more volatile than movements in the price of underlying investments. Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed. An investor may not get back the original amount invested. Changes in the rates of exchange between currencies may cause the value of investments to fluctuate. Fluctuation may be particularly marked in the case of a higher volatility fund and the value of an investment may fall suddenly and substantially. Shares in the biotechnology sector can prove volatile and above average price movements can be expected. There can be no assurance that the Company's investment objective will be achieved and investment results may vary substantially over time. This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Investment trust share prices may not fully reflect underlying net asset values. There may be a difference between the prices at which you may purchase ("the offer price") or sell ("the bid price") a share on the stock market which is known as "bid-offer" or "dealing" spread. This is set by the market makers and varies from share to share. This spread typically averages 1-2% each way on the mid-market price (the price halfway between the bid and offer prices), and can fluctuate and at times be higher than average. The net asset value per share is calculated in accordance with the guidelines of the Association of Investment Companies. Net assets are stated inclusive of income received. Any opinions on individual stocks are those of the Company's Portfolio Manager and no reliance should be given on any such views. Any research in this document has been procured and may have been acted upon by OrbiMed Capital LLC for its own purposes. The results are being made available to you only incidentally. The views expressed herein do not constitute investment or any other advice and are subject to change. They do not necessarily reflect the views of Frostrow Capital LLP and no assurances are made as to their accuracy.

www.worldwidewh.com

Fast Facts as at 30 November 2016

Launch Date	April 1995
Annual Management Fee (payable by the Company)	0.65% of net assets <u>plus</u> 0.30% of market cap. up to £150m, 0.20% > £150m and 0.125% > £500m <u>plus</u> £57,500
Performance Fee [^]	See Annual Report for details
Ongoing charges *	0.9%
Continuation Vote **	At the AGM every 5 years
Year / Half Year	31 March / 30 September
Capital Structure	46,362,983 Ordinary Shares 143,295 Treasury Shares

^{*}Calculated at the financial year end, includes management fees and all other operating expenses, and excludes performance fees.

^{**}Next vote to be held at the AGM in 2019.

[^] Under new fee arrangements which will become effective on 1 April 2017, Frostrow Capital will not receive a performance fee and their annual management fee will be amended. Further details can be found in the 2016 Half Year Report. This can be found on the Company's website.

Trust Characteristics

Number of Holdings	80
Net Assets (£m)	978.1
Market Capitalisation (£m)	967.6
Dividends	Provisional payment dates: January & July
Indicative Yield	0.8%
Gearing	2.9%
Leverage ***	Gross 115.6% Commitment 113.1%
Share Price (p)	2087.00
NAV(p) (cum income)	2109.73
(Discount) / Premium	(1.1%)
NAV(p) (cum income) Diluted for treasury shares	2109.66
(Discount) / Premium	(1.1%)

*** The Board has set the maximum leverage limit for both the Gross and the Commitment basis at 140% of the Company's Net Asset Value.

Codes

Sedol	0338530
ISIN	GB0003385308
Bloomberg	WWH LN
Epic	WWH

How to Contact Us

Frostrow Capital LLP
25 Southampton Buildings, London, WC2A 1AL
Tel.: 0203 0084910
Fax: 0203 0438889
Website: www.frostrow.com

Grant Challis
Tel.: 0203 0084912
grant.challis@frostrow.com

This financial promotion is issued by Frostrow Capital LLP which is authorised and regulated by the Financial Conduct Authority ("FCA").

